Genfit S.A. (GNFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.212x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€5.01 Million ≈ $5.86 Million USD) by net assets (€-23.64 Million ≈ $-27.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GNFT market cap overview for the company's overall valuation and market capitalisation.
Genfit S.A. - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genfit S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency. Explore Genfit S.A. (GNFT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
N/A |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
-0.019x |
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
0.048x |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
0.038x |
|
Hoang Anh Gia Lai JSC
VN:HAG
|
0.005x |
|
Getein Biotech Inc
SHG:603387
|
0.034x |
|
Fitipower Integrated Technology Inc
TW:4961
|
0.004x |
|
Perusahaan Perkebunan London Sumatra Indonesia Tbk PT
JK:LSIP
|
0.019x |
Annual Cash Flow Conversion Efficiency for Genfit S.A. (2003–2025)
The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2003 to 2025. View Genfit S.A. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-23.64 Million ≈ $-27.64 Million |
€-25.32 Million ≈ $-29.61 Million |
1.071x | +376.83% |
| 2024-12-31 | €69.22 Million ≈ $80.93 Million |
€15.55 Million ≈ $18.18 Million |
0.225x | +127.54% |
| 2023-12-31 | €67.95 Million ≈ $79.44 Million |
€-55.43 Million ≈ $-64.80 Million |
-0.816x | -6.15% |
| 2022-12-31 | €94.53 Million ≈ $110.51 Million |
€-72.64 Million ≈ $-84.92 Million |
-0.768x | -191.60% |
| 2021-12-31 | €119.10 Million ≈ $139.24 Million |
€99.92 Million ≈ $116.81 Million |
0.839x | -85.93% |
| 2020-12-31 | €-16.16 Million ≈ $-18.90 Million |
€-96.37 Million ≈ $-112.67 Million |
5.963x | +1151.31% |
| 2019-12-31 | €84.06 Million ≈ $98.28 Million |
€-47.68 Million ≈ $-55.74 Million |
-0.567x | +78.82% |
| 2018-12-31 | €20.94 Million ≈ $24.48 Million |
€-56.08 Million ≈ $-65.56 Million |
-2.678x | -459.93% |
| 2017-12-31 | €104.23 Million ≈ $121.85 Million |
€-49.86 Million ≈ $-58.29 Million |
-0.478x | -150.88% |
| 2016-12-31 | €142.80 Million ≈ $166.94 Million |
€-27.23 Million ≈ $-31.83 Million |
-0.191x | +28.95% |
| 2015-12-31 | €55.42 Million ≈ $64.79 Million |
€-14.87 Million ≈ $-17.38 Million |
-0.268x | -21.99% |
| 2014-12-31 | €70.43 Million ≈ $82.34 Million |
€-15.49 Million ≈ $-18.11 Million |
-0.220x | +66.27% |
| 2013-12-31 | €14.09 Million ≈ $16.48 Million |
€-9.19 Million ≈ $-10.75 Million |
-0.652x | +43.31% |
| 2012-12-31 | €6.83 Million ≈ $7.99 Million |
€-7.86 Million ≈ $-9.19 Million |
-1.150x | +27.92% |
| 2011-12-31 | €4.46 Million ≈ $5.21 Million |
€-7.11 Million ≈ $-8.32 Million |
-1.596x | -148.23% |
| 2010-12-31 | €8.39 Million ≈ $9.81 Million |
€-5.39 Million ≈ $-6.31 Million |
-0.643x | -4415.44% |
| 2009-12-31 | €15.52 Million ≈ $18.14 Million |
€-221.00K ≈ $-258.37K |
-0.014x | +93.83% |
| 2008-12-31 | €22.38 Million ≈ $26.17 Million |
€-5.16 Million ≈ $-6.04 Million |
-0.231x | -21.55% |
| 2007-12-31 | €25.37 Million ≈ $29.66 Million |
€-4.81 Million ≈ $-5.63 Million |
-0.190x | -202.28% |
| 2006-12-31 | €27.77 Million ≈ $32.47 Million |
€-1.74 Million ≈ $-2.04 Million |
-0.063x | -150.16% |
| 2005-12-31 | €13.39 Million ≈ $15.65 Million |
€1.68 Million ≈ $1.96 Million |
0.125x | -54.99% |
| 2004-12-31 | €14.00 Million ≈ $16.37 Million |
€3.89 Million ≈ $4.55 Million |
0.278x | +43.82% |
| 2003-12-31 | €9.04 Million ≈ $10.57 Million |
€1.75 Million ≈ $2.04 Million |
0.193x | -- |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase… Read more